Trial ID or NCT#



not recruiting iconNOT RECRUITING


This clinical trial studies gallium-68 (68Ga)-prostate specific membrane antigen (PSMA) (gallium Ga 68-labeled PSMA ligand Glu-urea-Lys[Ahx]) positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) in identifying tumors in patients with prostate cancer that has come back after a period of improvement (recurrent). 68Ga-PSMA is a radioactive drug that may attach to specific prostate cancer cells and light up. Scanners, such as PET/CT or PET/MRI, can then be used to take pictures of the body to see where the cancer is. Using 68Ga-PSMA for PET/CT or PET/MRI may allow doctors to identify smaller tumors than standard methods.

Official Title

68Ga-PSMA PET/CT or PET/MRI in the Evaluation of Patients With Prostate Cancer: A Feasibility Study

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: Male
Accepts Healthy Volunteers: No


Steven Hancock, MD
Steven Hancock, MD
Radiation oncologist, Internal medicine doctor
Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery at Stanford University Medical Center
Geoffrey Sonn
Geoffrey Sonn
Urologic oncologist, Urologist, Urologic specialist, Genitourinary specialist
Assistant Professor of Urology and, by courtesy, of Radiology at the Stanford University Medical Center
Andreas Loening
Andreas Loening
Diagnostic radiologist, Radiologist
Assistant Professor of Radiology (Body MRI) at the Stanford University Medical Center
Sandy Srinivas
Sandy Srinivas
Medical oncologist, Urologic specialist, Genitourinary specialist
Professor of Medicine (Oncology) and, by courtesy, of Urology at the Stanford University Medical Center
Andrei Iagaru
Andrei Iagaru
Professor of Radiology (Nuclear Medicine) at the Stanford University Medical Center

Contact us to find out if this trial is right for you.


Pamela Gallant
(650) 736-8965